Eli Lilly’s Alzheimer’s drug donanemab has speedy removed amyloid plaques in a pivotal Phase III trail halting disease progression for one year in half of patients.
Hosting leading industry experts from across Europe, Connect in Pharma 2023 revealed future trends in pharma and AI, sustainability, and preventative medicine during a two-day meeting in Geneva on 14 & 15 June.
https://european-biotechnology.com/wp-content/uploads/2024/04/_AAA1925.JPG10001500Margarita Milidakis/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMargarita Milidakis2023-07-17 13:46:382024-04-02 15:34:18Connect in Pharma 2023 revealed latest trends in pharmaceutical manufacturing and drug delivery
Although the EU Commission wants to abolish the internal combustion engine in individual transport through eMobility, biofuels are far from dead, according to a new study.
https://european-biotechnology.com/wp-content/uploads/2024/04/EG427.png417570Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2023-07-13 10:11:502024-07-09 14:55:18EG 427 expands Series A closing to €18m
Conventional meat production contributes to 15% of the global greenhouse gas emissions, high energy consumption and land use change. Belgian Paleo NV produces alternative protein from myoglobins of different species.
https://european-biotechnology.com/wp-content/uploads/2024/04/EB.com_Je__rome__Bedier-scaled.jpg25602278Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2023-07-12 07:50:242024-07-16 16:58:58New President for Flash Therapeutics
Mallia Therapeutics GmbH has raised seed money to accelerate preclinical research and start Phase I testing of a baldness cure with unique MOA named soluble CD83.
German CRO Evotec SE enters licence agreement Bristol Myers Squibb within its neuroscience partnership providing US$40m upfront, milestones and double-digit sales royalities.
https://european-biotechnology.com/wp-content/uploads/2024/04/BMS.jpg9311920Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2023-07-11 09:11:052024-07-09 14:52:10Evotec earns US$40m in global licence deal with BMS
Paris-based Nanobiotix SA has signed a potential US$1.8bn oncology deal with Janssen Pharmaceutica NV for the global commercialisation rights of its radioenhancer NBTXR3.
https://european-biotechnology.com/wp-content/uploads/2024/04/_c__Nanobiotix.jpg460690Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2023-07-10 12:47:592024-07-09 16:25:55Nanobiotix SA licences NBTXR3 to J&J
Lilly presents impressing results for Alzheimer’s drug donanemab
Latest NewsEli Lilly’s Alzheimer’s drug donanemab has speedy removed amyloid plaques in a pivotal Phase III trail halting disease progression for one year in half of patients.
Connect in Pharma 2023 revealed latest trends in pharmaceutical manufacturing and drug delivery
Sponsored PublicationsHosting leading industry experts from across Europe, Connect in Pharma 2023 revealed future trends in pharma and AI, sustainability, and preventative medicine during a two-day meeting in Geneva on 14 & 15 June.
Biomethane fuel offers negative carbon footprint
Latest NewsAlthough the EU Commission wants to abolish the internal combustion engine in individual transport through eMobility, biofuels are far from dead, according to a new study.
Carbios raises €141m to boost enzymatic PET recycling
Latest NewsIn an oversubscribed capital increase, Carbios SAS has raised €141m, the largest on Euronext growth since 2015.
EG 427 expands Series A closing to €18m
Latest NewsParis-based gene therapy vector specialist EG 427 SAS has closed a Series A financing at €18m raising additional €5m in the final closing.
Tasteful plant protein
BackgroundConventional meat production contributes to 15% of the global greenhouse gas emissions, high energy consumption and land use change. Belgian Paleo NV produces alternative protein from myoglobins of different species.
New President for Flash Therapeutics
AppointmentsToulouse-based Flash Therapeutics has appointed Jerome Bedier as its new President.
Seed money for unique topical hair growth inducer
Latest NewsMallia Therapeutics GmbH has raised seed money to accelerate preclinical research and start Phase I testing of a baldness cure with unique MOA named soluble CD83.
Evotec earns US$40m in global licence deal with BMS
Latest NewsGerman CRO Evotec SE enters licence agreement Bristol Myers Squibb within its neuroscience partnership providing US$40m upfront, milestones and double-digit sales royalities.
Nanobiotix SA licences NBTXR3 to J&J
Latest NewsParis-based Nanobiotix SA has signed a potential US$1.8bn oncology deal with Janssen Pharmaceutica NV for the global commercialisation rights of its radioenhancer NBTXR3.